1. Component Analysis
This protocol combines the current “gold standard” pharmaceutical weight loss drugs (Semaglutide/Tirzepatide) with specific “fat mobilization” and “mitochondrial” peptides to accelerate results and prevent metabolic slowdown.
- Semaglutide (Option A):
- Role: GLP-1 Agonist. The active ingredient in Ozempic and Wegovy. It suppresses appetite, slows gastric emptying, and improves insulin sensitivity.
- Tirzepatide (Option B):
- Role: Dual GLP-1 / GIP Agonist. The active ingredient in Mounjaro and Zepbound. It is generally more potent than Semaglutide because it targets two receptors, often leading to greater weight loss and better glucose control.
- AOD-9604:
- Role: “Anti-Obesity Drug” (Fragment of Growth Hormone).
- Mechanism: It mimics the lipolytic (fat-burning) section of the Growth Hormone molecule without the effects on blood sugar or muscle growth. It is used here to mobilize stored fat specifically.
- MOTS-c:
- Role: Mitochondrial-Derived Peptide.
- Mechanism: Often called “exercise in a bottle,” it acts on the mitochondria to regulate metabolic homeostasis. It improves glucose metabolism, increases fatty acid oxidation, and prevents age-related insulin resistance.
